OTCMKTS:IGXT IntelGenx Technologies (IGXT) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free IGXT Stock Alerts $0.17 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.17▼$0.1750-Day Range$0.15▼$0.1952-Week Range$0.09▼$0.22VolumeN/AAverage Volume138,881 shsMarket Capitalization$29.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get IntelGenx Technologies alerts: Email Address Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About IntelGenx Technologies Stock (OTCMKTS:IGXT)IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Read More IGXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGXT Stock News HeadlinesMay 17 at 5:39 PM | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 17 at 10:04 AM | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 8, 2024 | globenewswire.comIntelGenx Announces Voting Results on Election of DirectorsApril 8, 2024 | finance.yahoo.comIntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical TrialApril 8, 2024 | globenewswire.comIntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical TrialApril 5, 2024 | globenewswire.comIntelGenx Updates Status of Buprenorphine Buccal Film ANDAMarch 23, 2024 | seekingalpha.comIntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | insidermonkey.comIntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | investorplace.comIGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023March 21, 2024 | globenewswire.comIntelGenx Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 16, 2024 | seekingalpha.comIGXT IntelGenx Technologies Corp.March 14, 2024 | globenewswire.comIntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to FollowMarch 11, 2024 | globenewswire.comIntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life SciencesFebruary 20, 2024 | finance.yahoo.comUPDATE -- IntelGenx Launches Preferred Share Regulation A OfferingFebruary 20, 2024 | globenewswire.comUPDATE -- IntelGenx Launches Preferred Share Regulation A OfferingFebruary 20, 2024 | globenewswire.comIntelGenx Launches Preferred Share Regulation A OfferingFebruary 19, 2024 | finance.yahoo.comIntelGenx Technologies Corp. (IGXT)February 5, 2024 | finance.yahoo.comStudies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® PlatformDecember 7, 2023 | morningstar.comIntelgenx Technologies Corp IGXTNovember 14, 2023 | finance.yahoo.comIntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's DiseaseNovember 13, 2023 | finance.yahoo.comIntelGenx Reminds Shareholders to Vote at Upcoming Special MeetingNovember 10, 2023 | insidermonkey.comIntelGenx Technologies Corp. (PNK:IGXT) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comIntelGenx Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comIntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with TilraySeptember 21, 2023 | finance.yahoo.comIntelGenx Provides RIZAFILM® U.S. Commercialization UpdateSee More Headlines Receive IGXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IGXT CUSIP45822R101 CIK1098880 Webwww.intelgenx.com Phone(514) 331-7440Fax514-331-0436Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,930,000.00 Net Margins-1,049.48% Pretax Margin-1,049.48% Return on EquityN/A Return on Assets-158.32% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.40 Sales & Book Value Annual Sales$1.04 million Price / Sales28.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-1.86Miscellaneous Outstanding Shares174,660,000Free Float101,214,000Market Cap$29.17 million OptionableNot Optionable Beta2.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Dwight Gorham (Age 66)Chief Executive Officer Comp: $230.56kMr. André Godin C.A. (Age 60)CPA, CA, CPA, President & CFO Comp: $261.62kMr. Tommy Kenny J.D. (Age 37)L.L.B., M.Sc., Senior VP & General Counsel Comp: $152.62kMs. Nadine Paiement M.Sc. (Age 47)Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp Comp: $156.5kMs. Karen Kalayajian CPA (Age 44)Vice President of Finance & Administration Stephen KilmerInvestor Relations OfficerMs. Ingrid Zerbe (Age 70)Corporate Secretary Zenoz Nina PourhassanVP of Quality Operations of SubsidiaryMore ExecutivesKey CompetitorsLipocineNASDAQ:LPCNDURECTNASDAQ:DRRXTheratechnologiesNASDAQ:THTXEnlivex TherapeuticsNASDAQ:ENLVPharmaxisOTCMKTS:PXSLYView All Competitors IGXT Stock Analysis - Frequently Asked Questions How have IGXT shares performed in 2024? IntelGenx Technologies' stock was trading at $0.1381 at the beginning of the year. Since then, IGXT stock has increased by 20.9% and is now trading at $0.1670. View the best growth stocks for 2024 here. Are investors shorting IntelGenx Technologies? IntelGenx Technologies saw a decrease in short interest in April. As of April 30th, there was short interest totaling 600 shares, a decrease of 98.9% from the April 15th total of 54,800 shares. Based on an average trading volume of 281,800 shares, the days-to-cover ratio is presently 0.0 days. View IntelGenx Technologies' Short Interest. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) issued its earnings results on Thursday, March, 21st. The company reported ($0.02) EPS for the quarter. The company had revenue of $0.43 million for the quarter. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), Zevra Therapeutics (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI), BIOLASE (BIOL) and Ocugen (OCGN). How do I buy shares of IntelGenx Technologies? Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IGXT) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.